If the clinical trials for ALS and PD are any indication, increasing NAD+ availability, using NR or NMN, will likely need to be paired with another treatment, such as an Sirt activator, Parp inhibitor, or a previously approved drug for HD treatment, to achieve the most positive results. Here, PARP1 is linked to Huntington disease.